DE-ESCALATE

Prostate Cancer is themost common cancer in men.

De-ESCALATE project

Metastatic Prostate Cancer

Despite the dramatic improvements in early diagnostic and local treatment, one out of five prostate cancer patients will die from their disease. Therefore, it remains critical to improve the present strategy for advanced and metastatic prostate cancer.

Learn more

Multidisciplinary

We are a multidisciplinary and multistakeholder consortium involving clinical oncologists, surgeons, health economists and patient representatives. The study design was successfully discussed with patients. This action is part of the Cancer Mission cluster of projects on ‘Diagnosis and treatment’.

About De-Escalate

iADT vs. Continuous Treatment in Metastatic Prostate Cancer

In the DE-ESCALATE project, we will evaluate whether intermittent intensified androgen deprivation treatment (iADT) in metastatic prostate cancer is not inferior to continuous treatment in terms of oncological benefit while minimizing side effects and resource utilization and improving patient quality of life. The proposed clinical trial is designed to detect early if iADT has a negative impact on overall survival compared to continuous therapy.